213 related articles for article (PubMed ID: 36313631)
1. IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N
Zhang J; Yang K; Bu J; Yan J; Hu X; Liu K; Gao S; Tang S; Gao L; Chen W
Front Oncol; 2022; 12():1035871. PubMed ID: 36313631
[TBL] [Abstract][Full Text] [Related]
2. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma.
Du M; Peng Y; Li Y; Sun W; Zhu H; Wu J; Zong D; Wu L; He X
Cell Death Discov; 2022 Feb; 8(1):53. PubMed ID: 35136045
[TBL] [Abstract][Full Text] [Related]
3. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
4. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization.
Qin J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H; Cai J
Transl Oncol; 2023 Nov; 37():101764. PubMed ID: 37643553
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
7. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
8. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner.
Wang X; Lu X; Wang P; Chen Q; Xiong L; Tang M; Hong C; Lin X; Shi K; Liang L; Lin J
J Transl Med; 2022 May; 20(1):198. PubMed ID: 35509101
[TBL] [Abstract][Full Text] [Related]
9. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
[TBL] [Abstract][Full Text] [Related]
10. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.
Chen J; Yu Y; Chen X; He Y; Hu Q; Li H; Han Q; Ren F; Li J; Li C; Bao J; Ren Z; Duan Z; Cui G; Sun R
Cell Prolif; 2018 Dec; 51(6):e12510. PubMed ID: 30105813
[TBL] [Abstract][Full Text] [Related]
11. IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
Lv L; Wei Q; Zhang J; Dong Y; Shan Z; Chang N; Zhao Y; Bian P; Yi Q
Cell Mol Biol Lett; 2024 Mar; 29(1):39. PubMed ID: 38504159
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of IGF2BP3 inhibits the tumorigenesis of gallbladder cancer and modifies tumor microenvironment.
Qin Y; Zhang M; Lei H; Wu H; Huang C; Zhou X; Fu Y; Weng M; Ma M
Drug Dev Res; 2022 Dec; 83(8):1831-1844. PubMed ID: 36184877
[TBL] [Abstract][Full Text] [Related]
13.
Zhu H; Chen Z; Yu J; Wu J; Zhuo X; Chen Q; Liang Y; Li G; Wan Y
Ann Transl Med; 2022 Aug; 10(16):893. PubMed ID: 36111048
[TBL] [Abstract][Full Text] [Related]
14. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract][Full Text] [Related]
15. The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma.
Chen B; Huang R; Xia T; Wang C; Xiao X; Lu S; Chen X; Ouyang Y; Deng X; Miao J; Zhao C; Wang L
Oncogene; 2023 Nov; 42(48):3564-3574. PubMed ID: 37853162
[TBL] [Abstract][Full Text] [Related]
16. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
17. N
Zheng X; Li S; Yu J; Dai C; Yan S; Chen G; Sun C
Transl Cancer Res; 2023 Apr; 12(4):992-1005. PubMed ID: 37180667
[TBL] [Abstract][Full Text] [Related]
18. The RNA m
Ge L; Rui Y; Wang C; Wu Y; Wang H; Wang J
Cell Death Dis; 2024 Mar; 15(3):192. PubMed ID: 38448411
[TBL] [Abstract][Full Text] [Related]
19. NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14.
Yang ZY; Zhao C; Liu SL; Pan LJ; Zhu YD; Zhao JW; Wang HK; Ye YY; Qiang J; Shi LQ; Mei JW; Xie Y; Gong W; Shu YJ; Dong P; Xiang SS
Cancer Lett; 2024 Apr; 587():216703. PubMed ID: 38341127
[TBL] [Abstract][Full Text] [Related]
20. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
